Savara Inc.

NASDAQ•SVRA

CEO: Mr. Matthew Pauls J.D., M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2017-04-28

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

連絡先情報

1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, 19047, United States

512-614-1848

www.savarapharma.com

時価総額

$1.21B

PER (TTM)

-11.1

配当利回り

52週高値

$7.01

52週安値

$1.89

52週レンジ

79%

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.13+0.00%

直近4四半期の推移

フリーCF

-$25.06M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

MOLBREEVI BLA Filed BLA for MOLBREEVI resubmitted Dec 2025; FDA formally filed Feb 2026 with Priority Review designation.

IMPALA-2 Trial Positive Results Primary endpoint DLCO showed 6.0 percentage points improvement over placebo (p=0.0007), indicating durability of effect.

Financing Secured Post-Trial October 2025 offering raised $140.2 M net proceeds; debt facility provides potential $75 M more upon approval.

Cash Position Strong Cash and investments totaled $235.7 M as of December 31, 2025, supporting ongoing clinical development activities.

リスク要因

Dependence on Single Candidate Business success substantially dependent on MOLBREEVI clinical development, regulatory approval, and commercial success.

Continued Operating Losses Incurred $118.8 M net loss in 2025; expect substantial losses requiring future capital raises for operations.

G&A Expense Surge General and administrative expenses rose 68.0% to $42.1 M in 2025 driven by strategic workforce expansion efforts.

Regulatory Approval Uncertainty Regulatory authorities retain discretion to delay or deny approval, potentially preventing timely marketing of MOLBREEVI.

見通し

Advance Regulatory Approval Continue pursuing MOLBREEVI regulatory approval in U.S., EU, and UK following BLA filing in February 2026.

Establish Dual Supply Chain Plan to qualify a second source drug product manufacturer following approval to establish a dual-source supply chain.

Prepare Commercial Launch Will need to increase organization size and establish sales and marketing infrastructure upon receiving regulatory approval.

Pediatric Trial Progress Pediatric IMPACT trial for autoimmune PAP is currently ongoing following acceptance by EMA and MHRA.

同業比較

売上高 (TTM)

GERN

$183.88M

+138.8%

RGNX

$170.44M

+104.5%

MGTX

$81.39M

+144.6%

粗利益率 (最新四半期)

NBTX

100.0%

+0.0pp

ATXS

100.0%

+0.0pp

MGTX

99.4%

+33.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TNGX	$2.50B	-24.7	-50.3%	8.4%
TYRA	$1.91B	-17.7	-41.2%	2.1%
NBTX	$1.55B	-52.2	31.2%	140.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし